• GTP Solution in p21 mRNA–LNP Bladder Cancer Therapy: Mechani

  2026-06-17

  This thought-leadership article explores the pivotal mechanistic role and translational opportunities of high-purity GTP Solution in the synthesis of p21 mRNA–LNPs for advanced bladder cancer therapy. Bridging molecular insight, protocol guidance, and clinical translation, it offers strategic advice for researchers aiming to accelerate localized mRNA-based treatments, with evidence-driven recommendations and a forward-looking perspective on the evolving landscape.

• Ferrostatin-1 (Fer-1): Optimizing Ferroptosis Assays in Dise

  2026-06-17

  Ferrostatin-1 (Fer-1) is a nanomolar-potency ferroptosis inhibitor that empowers precision oxidative lipid damage inhibition in cancer, neurodegeneration, and liver disease models. This in-depth guide translates bench protocols and troubleshooting strategies—anchored by the latest evidence—so researchers can maximize assay reliability and mechanistic insight.

• 2'-O-Methyladenosine: Unraveling Its Role in RNA Modificatio

  2026-06-16

  Explore the unique biochemical functions of 2'-O-Methyladenosine nucleoside, its quantification, and research applications in RNA modification studies. Gain practical insights for advanced cell-based assays and purine metabolism analysis.

• ML-7 Hydrochloride in Ischemia/Reperfusion Models: Proteomic

  2026-06-16

  Explore how ML-7 hydrochloride, a potent myosin light chain kinase inhibitor, advances ischemia/reperfusion injury research by modulating proteomic responses and early cardiomyocyte cell death. This article offers a deeper proteomics-centric and assay design perspective not found in other reviews.

• Ibrexafungerp Activity Against Echinocandin-Resistant Candid

  2026-06-15

  This study systematically evaluated ibrexafungerp (MK 3118) against a large panel of clinically relevant, echinocandin-resistant Candida isolates. The findings highlight ibrexafungerp’s preserved in vitro activity—especially in certain FKS-mutant backgrounds—offering researchers new angles for antifungal resistance investigations.

• Microglial Nr4a1 and C3 Drive Synaptic Loss in TMJ Inflammat

  2026-06-15

  This study uncovers how microglial Nr4a1 deficiency and neuronal C3 deposition mediate excessive hippocampal synaptic pruning and depression-like behavior in mice with TMJ inflammation. The findings advance understanding of neuroimmune mechanisms behind TMD-associated mood disorders and suggest new molecular targets for intervention.

• LncRNA FAISL Blocks Calpain-2 FAK Cleavage in TNBC Progressi

  2026-06-14

  The referenced study uncovers how lncRNA FAISL promotes triple negative breast cancer (TNBC) progression by inhibiting Calpain-2-mediated proteolysis of focal adhesion kinase (FAK), stabilizing FAK protein and enhancing metastatic potential. This mechanistic insight offers a new perspective on FAK regulation and highlights lncRNA FAISL as a candidate for targeted intervention in aggressive breast cancer.

• Cl-Amidine trifluoroacetate salt: PAD4 Inhibition in Cancer

  2026-06-13

  Cl-Amidine (trifluoroacetate salt) empowers researchers to dissect PAD4-driven gene regulation in models of cancer, autoimmunity, and inflammation with unprecedented specificity. This guide decodes the latest applied protocols, troubleshooting tactics, and experimental insights, connecting frontline leukemia research to practical PAD4 inhibition workflows.

• RP3-340N1.2 Knockdown Impairs NSCLC via IL-6 mRNA Destabiliz

  2026-06-12

  This study uncovers a novel mechanism by which the lncRNA RP3-340N1.2 promotes non-small cell lung cancer (NSCLC) progression through stabilization of IL-6 mRNA. Targeted knockdown of RP3-340N1.2 enhances IL-6 mRNA degradation, suppressing tumor cell proliferation, migration, and pro-tumor macrophage polarization—highlighting a potential RNA-based therapeutic target in NSCLC.

• M344: Advancing HDAC Inhibition in Cancer and HIV Research

  2026-06-12

  M344, a potent histone deacetylase inhibitor, is reshaping translational research in oncology and virology. This article offers mechanistic insights and strategic guidance for leveraging M344 in cell differentiation, apoptosis, and viral latency models. By synthesizing current evidence, expert protocols, and competitive benchmarking, we highlight how M344 enables new approaches to therapy resistance and latent infection challenges.

• Radicicol Beyond Hsp90: Multi-Pathway Modulation in Disease

  2026-06-11

  Explore how Radicicol, a potent Hsp90 inhibitor, uniquely enables multi-pathway analysis in disease models—including apoptosis, adipogenesis, and inflammatory assays. This deep dive reveals Radicicol’s mechanistic versatility, advanced assay considerations, and its role in the evolving landscape of metabolic and cancer research.

• EV-Transferred ACLY Drives TAM Differentiation in HCC Progre

  2026-06-11

  This study reveals that hepatocellular carcinoma (HCC) cells secrete extracellular vesicles carrying ATP-citrate lyase (ACLY), which are taken up by monocytes to induce their differentiation into immunosuppressive tumor-associated macrophages (TAMs). These findings illuminate a metabolic mechanism by which HCC modulates the tumor microenvironment and suggest new avenues for immunotherapy targeting EV-mediated enzyme transfer.

• Itraconazole for Advanced Antifungal Biofilm Research

  2026-06-10

  Itraconazole, a triazole antifungal agent, is redefining research workflows in the fight against biofilm-mediated resistance in Candida species. This guide translates the latest mechanistic insights and protocol advances into actionable strategies for optimizing antifungal drug interaction studies and disseminated candidiasis models.

• OTUD3 Stabilizes SLC7A11 to Drive Sunitinib Resistance in cc

  2026-06-10

  This study uncovers how OTUD3 overexpression in clear cell renal cell carcinoma (ccRCC) stabilizes the cystine transporter SLC7A11, suppressing ferroptosis and promoting resistance to sunitinib. These mechanistic insights highlight new therapeutic targets and reinforce the importance of precise lipid peroxidation measurement in translational oncology research.

• Ferrostatin-1 (Fer-1): Optimizing Ferroptosis Assays in Canc

  2026-06-09

  Ferrostatin-1 (Fer-1) enables precise and reproducible inhibition of ferroptosis, streamlining mechanistic studies in cancer and neurodegenerative models. This article integrates novel findings and advanced workflows to help researchers maximize assay sensitivity and troubleshoot common pitfalls in oxidative lipid damage inhibition.

15294 records 1/1020 page Next 12345 下5页 Last page